Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 140
9
Diseases
17
Unique genes
0.338
Avg. similarity score
Caffey disease
Most-connected disease (7 links)
Disease
Searched: A4GALT-congenital disorder of glycosylation
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
A4GALT-congenital disorder of glycosylation
Caffey disease
Maternal hypertension
Rhizomelia
COL1A1-related Ehlers-Danlos syndrome
Combined osteogenesis imperfecta and ehlers-danlos syndrome
Cortical congenital hyperostosis
Dermatofibrosarcoma protuberans
Cholangitis
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Caffey disease | 7 | 7 | 1 |
| Maternal hypertension | 7 | 7 | 1 |
| Rhizomelia | 7 | 7 | 1 |
| COL1A1-related Ehlers-Danlos syndrome | 6 | 6 | 1 |
| Combined osteogenesis imperfecta and ehlers-danlos syndrome | 5 | 5 | 2 |
| Cortical congenital hyperostosis | 5 | 5 | 2 |
| Dermatofibrosarcoma protuberans | 5 | 5 | 2 |
| Cholangitis | 3 | 3 | 14 |
| A4GALT-congenital disorder of glycosylation | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| COL1A1 | 8 / 9 | Caffey disease, Cholangitis, COL1A1-related Ehlers-Danlos syndrome, Combined osteogenesis imperfecta and ehlers-danlos syndrome and 4 more |
| A4GALT | 2 / 9 | A4GALT-congenital disorder of glycosylation, Cortical congenital hyperostosis |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Non-integrin membrane-ECM interactions | Reactome | 3 / 24 | 88.3× | 4.68e-6 | 1.75e-4 ✓ sig. |
| AGE-RAGE signaling pathway in diabetic complications | KEGG | 4 / 101 | 28.0× | 1.03e-5 | 3.34e-4 ✓ sig. |
| Amoebiasis | KEGG | 4 / 103 | 27.4× | 1.11e-5 | 3.56e-4 ✓ sig. |
| Interleukin-4 and Interleukin-13 signaling | Reactome | 4 / 108 | 26.2× | 1.34e-5 | 4.18e-4 ✓ sig. |
| ECM proteoglycans | Reactome | 3 / 51 | 41.6× | 4.70e-5 | 1.18e-3 ✓ sig. |
| Platelet Aggregation (Plug Formation) | Reactome | 2 / 8 | 177× | 5.25e-5 | 1.29e-3 ✓ sig. |
| Platelet Adhesion to exposed collagen | Reactome | 2 / 11 | 128× | 1.03e-4 | 2.24e-3 ✓ sig. |
| PI3K-Akt signaling pathway | KEGG | 5 / 361 | 9.8× | 1.10e-4 | 2.35e-3 ✓ sig. |
| Renal cell carcinoma | KEGG | 3 / 70 | 30.3× | 1.22e-4 | 2.55e-3 ✓ sig. |
| GP1b-IX-V activation signalling | Reactome | 2 / 12 | 118× | 1.23e-4 | 2.58e-3 ✓ sig. |
| Focal adhesion | KEGG | 4 / 203 | 13.9× | 1.59e-4 | 3.17e-3 ✓ sig. |
| Proteoglycans in cancer | KEGG | 4 / 204 | 13.9× | 1.62e-4 | 3.22e-3 ✓ sig. |
| Integrin cell surface interactions | Reactome | 3 / 81 | 26.2× | 1.88e-4 | 3.62e-3 ✓ sig. |
| Extracellular matrix organization | Reactome | 2 / 15 | 94.2× | 1.96e-4 | 3.74e-3 ✓ sig. |
| Anchoring fibril formation | Reactome | 2 / 15 | 94.2× | 1.96e-4 | 3.74e-3 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| positive regulation of miRNA transcription | GO:1902895 | 4 / 56 | 78.5× | 1.67e-7 | 1.86e-5 ✓ sig. |
| blood vessel development | GO:0001568 | 4 / 70 | 62.8× | 4.14e-7 | 3.98e-5 ✓ sig. |
| cellular response to mycophenolic acid | GO:0071506 | 2 / 2 | 1,099× | 7.79e-7 | 6.73e-5 ✓ sig. |
| positive regulation of hormone biosynthetic process | GO:0046886 | 2 / 3 | 733× | 2.34e-6 | 1.64e-4 ✓ sig. |
| regulation of transforming growth factor beta2 production | GO:0032909 | 2 / 4 | 550× | 4.67e-6 | 2.87e-4 ✓ sig. |
| connective tissue replacement involved in inflammatory response wound healing | GO:0002248 | 2 / 5 | 440× | 7.78e-6 | 4.33e-4 ✓ sig. |
| response to hypoxia | GO:0001666 | 4 / 176 | 25.0× | 1.64e-5 | 7.75e-4 ✓ sig. |
| collagen fibril organization | GO:0030199 | 3 / 65 | 50.7× | 2.64e-5 | 1.11e-3 ✓ sig. |
| response to wounding | GO:0009611 | 3 / 81 | 40.7× | 5.11e-5 | 1.84e-3 ✓ sig. |
| skin morphogenesis | GO:0043589 | 2 / 13 | 169× | 6.04e-5 | 2.08e-3 ✓ sig. |
| collagen metabolic process | GO:0032963 | 2 / 18 | 122× | 1.18e-4 | 3.43e-3 ✓ sig. |
| transforming growth factor beta receptor signaling pathway | GO:0007179 | 3 / 112 | 29.4× | 1.34e-4 | 3.77e-3 ✓ sig. |
| negative regulation of gene expression | GO:0010629 | 4 / 339 | 13.0× | 2.10e-4 | 5.23e-3 ✓ sig. |
| embryonic placenta development | GO:0001892 | 2 / 26 | 84.6× | 2.50e-4 | 5.91e-3 ✓ sig. |
| negative regulation of miRNA transcription | GO:1902894 | 2 / 27 | 81.4× | 2.70e-4 | 6.25e-3 ✓ sig. |